Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis

Several potential biomarkers were collected in patients on the REACH2 trial at set timepoints and analyzed for the probability of treatment response of acute GVHD to ruxolitinib or best available therapy (BAT). They were categorized into one of the three classes as follows: acute GVHD-associated cytokines/chemokines (CXCL9, CXCL10, CXCL11, HGF, ST2, IL-2Rα, REG-3α, SPP1, TIM-3, PI3, BAFF, TNFRSF1A), immune cells (B cells, CD4+ T cells, CD8+ T cells, NK cells, TH17 cells, Treg cells), and inflammatory proteins (IFN-γ, IL-6, IL-8). Lower acute GVHD and immune cell markers before treatment positively affected the probability of a response to treatment.